Literature DB >> 17663679

Dyskeratosis congenita: advances in the understanding of the telomerase defect and the role of stem cell transplantation.

Josu de la Fuente1, Inderjeet Dokal.   

Abstract

DC is a multisystem bone marrow failure syndrome exhibiting marked clinical and genetic heterogeneity. X-linked, autosomal dominant and autosomal recessive subtypes are recognized. The gene mutated in X-linked DC (DKC1) encodes a highly conserved nucleolar protein called dyskerin. Dyskerin associates with the H/ACA motif class of small nucleolar RNAs in small nucleolar ribonucleoprotein particles that are important in guiding the conversion of uracil to pseudouracil during the maturation of ribosomal RNA. Dyskerin also associates with the TERC, which is important in the maintenance of telomeres. Mutations in TERC have been identified in patients with autosomal dominant DC and in a subset of patients with aplastic anemia and myelodysplasia. Recently, heterozygous mutations in TERT have been found in some patients with autosomal dominant DC and aplastic anemia. Additionally, patients with the severe multisystem disorder, Hoyeraal-Hreidarsson syndrome, have been found to have DKC1 mutations. Collectively, these observations have demonstrated that classical DC, Hoyeraal-Hreidarsson syndrome and a subset of aplastic anemia are due to a primary defect in telomerase. The critical role of telomeres and telomerase in humans is seen in the multisystem abnormalities found in these patients, including the increased incidence of malignancy. As bone marrow failure is the principal cause of death, conventional allografts have been attempted with limited success due to the high rate of pulmonary and endothelial complications. However, outcomes have improved with the use of non-myeloablative protocols, although the follow up is too short to evaluate long term toxicity and the natural course of the disease and it may be that correction of the telomerase defect is essential for the treatment of these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17663679     DOI: 10.1111/j.1399-3046.2007.00721.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  45 in total

Review 1.  Telomerase and idiopathic pulmonary fibrosis.

Authors:  Mary Armanios
Journal:  Mutat Res       Date:  2011-11-04       Impact factor: 2.433

2.  Reduced intensity conditioning regimen with fludarabine, cyclophosphamide, low dose TBI and alemtuzumab leading to successful unrelated umbilical cord stem cell engraftment and survival in two children with dyskeratosis congenita.

Authors:  M Brown; D Myers; N Shreve; R Rahmetullah; M Radhi
Journal:  Bone Marrow Transplant       Date:  2016-01-25       Impact factor: 5.483

3.  Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010.

Authors:  Michael A Pulsipher; Neal S Young; Jakub Tolar; Antonio M Risitano; H Joachim Deeg; Paolo Anderlini; Rodrigo Calado; Seiji Kojima; Mary Eapen; Richard Harris; Phillip Scheinberg; Sharon Savage; Jaroslaw P Maciejewski; Ramon V Tiu; Nancy DiFronzo; Mary M Horowitz; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-27       Impact factor: 5.742

4.  Telomere dysfunction causes alveolar stem cell failure.

Authors:  Jonathan K Alder; Christina E Barkauskas; Nathachit Limjunyawong; Susan E Stanley; Frant Kembou; Rubin M Tuder; Brigid L M Hogan; Wayne Mitzner; Mary Armanios
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-03       Impact factor: 11.205

Review 5.  Extrahematopoietic manifestations of the short telomere syndromes.

Authors:  Kristen E Schratz
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 6.  Telomeres and age-related disease: how telomere biology informs clinical paradigms.

Authors:  Mary Armanios
Journal:  J Clin Invest       Date:  2013-03-01       Impact factor: 14.808

Review 7.  Bone marrow failure and the telomeropathies.

Authors:  Danielle M Townsley; Bogdan Dumitriu; Neal S Young
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

Review 8.  Dyskeratosis congenita, stem cells and telomeres.

Authors:  Michael Kirwan; Inderjeet Dokal
Journal:  Biochim Biophys Acta       Date:  2009-02-07

Review 9.  The role of telomere biology in bone marrow failure and other disorders.

Authors:  Sharon A Savage; Blanche P Alter
Journal:  Mech Ageing Dev       Date:  2007-11-19       Impact factor: 5.432

Review 10.  The telomere syndromes.

Authors:  Mary Armanios; Elizabeth H Blackburn
Journal:  Nat Rev Genet       Date:  2012-09-11       Impact factor: 53.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.